Advertisement
Singapore markets close in 4 hours 21 minutes

  • Straits Times Index

    3,168.91
    -18.75 (-0.59%)
     

  • Nikkei

    37,137.48
    -942.22 (-2.47%)
     

  • Hang Seng

    16,184.02
    -201.85 (-1.23%)
     

  • FTSE 100

    7,877.05
    +29.06 (+0.37%)
     

  • Bitcoin USD

    62,717.94
    +775.77 (+1.25%)
     

  • CMC Crypto 200

    1,286.25
    +400.71 (+44.00%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • Dow

    37,775.38
    +22.07 (+0.06%)
     

  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     

  • Gold

    2,402.20
    +4.20 (+0.18%)
     

  • Crude Oil

    84.71
    +1.98 (+2.39%)
     

  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     

  • FTSE Bursa Malaysia

    1,550.95
    +6.19 (+0.40%)
     

  • Jakarta Composite Index

    7,065.44
    -101.37 (-1.41%)
     

  • PSE Index

    6,411.73
    -111.46 (-1.71%)
     

Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023

Business Wire
·1-min read

DURHAM, N.C., May 02, 2023--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2023 and provide a business update on May 9, 2023.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230502005091/en/

Contacts

Investor and Media Contact:
Mei Burris
Director, Investor Relations and Finance
Mei.Burris@precisionbiosciences.com